TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Bioxyne Limited ( (AU:BXN) ).
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured an exclusive agreement with Curaleaf International to import, manufacture, and distribute the Que Medical Inhalation Device in Australia. This device, designed for medical cannabis liquid inhalants, is set to launch in November 2025, marking a significant expansion in Bioxyne’s operations and strengthening its position in the medical device sector. The partnership is expected to generate a strong revenue stream, supporting Bioxyne’s financial targets and enhancing access to regulated inhalation technology in Australia.
More about Bioxyne Limited
Bioxyne Limited is an Australian pharmaceutical and healthcare company that manufactures and distributes novel medicines and health products, including medicinal cannabis, MDMA, and Psilocybin. Its subsidiary, Breathe Life Sciences, is a GMP-licensed manufacturer and distributor of controlled substances, with operations in Australia, Japan, the UK, and Czechia.
Average Trading Volume: 4,336,245
Technical Sentiment Signal: Buy
Current Market Cap: A$87.59M
Learn more about BXN stock on TipRanks’ Stock Analysis page.